The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
Edwards CJ, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, Yadin D, Hayes P, Stelter S, Bartlett PD, Zuazo M, Garcia-Granda MJ, Benedetti G, Fiaska S, Birkett NR, Teng Y, Enever C, Arasanz H, Bocanegra A, Chocarro L, Fernandez G, Vera R, Archer B, Osuch I, Lewandowska M, Surani YM, Kochan G, Escors D, Legg J, Pierce AJ.
Edwards CJ, et al. Among authors: stelter s.
Br J Cancer. 2022 May;126(8):1168-1177. doi: 10.1038/s41416-021-01684-4. Epub 2021 Dec 30.
Br J Cancer. 2022.
PMID: 34969998
Free PMC article.